ASN-7350 / Asieris - LARVOL DELTA

ASN-7350, a highly selective FGFR2/3 dual inhibitor, for FGFR2/FGFR3 driven solid tumors (AACR 2025) - "Alterations in fibroblast growth factor receptors (FGFRs) are recognized as oncogenic drivers in numerous human cancers. Notably, ASN-8639 was more efficacious than reference FGFR2 inhibitor in the endometrial tumor model with erdafitinib-resistant FGFR2-N549K mutation at the same dose. These findings support the further clinical development of ASN-8639 as a potential best-in-class FGFR2/3 dual inhibitor for the treatment of bladder, endometrial, and other solid tumors with FGFR2/3 aberrations."

Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Oncology • Solid Tumor • Urothelial Cancer • FGFR1 • FGFR2 • FGFR3 • FGFR4 • TACC3

ASN-7350, a highly selective FGFR2/3 dual inhibitor, for FGFR2/FGFR3 driven solid tumors (Asieris Pharma Press Release) - "Addressing the issues of FGFR1/4-related toxicities and acquired resistance associated with existing pan-FGFR inhibitors, ASN-7350 achieves selective inhibition through a non-covalent binding mechanism. In preclinical studies, it has demonstrated superior broad-spectrum anti-tumor activity compared to peer candidates (e.g., RLY-4008, TYRA-300). This compound effectively overcomes FGFR2/3 resistance mutations while exhibiting a significantly widened therapeutic window, making it applicable for various FGFR2/3-driven solid tumors including bladder cancer, endometrial cancer, and gastric cancer. The project has entered the IND-enabling study and is targeting regulatory approval by the end of 2025."

IND • Preclinical • Bladder Cancer • Endometrial Cancer • Gastric Cancer

Focusing on strategic expansion in key areas and fast-tracking high-impact R&D initiatives (PRNewswire) - "Progress on APL-2501 (CLDN6/9 ADC) is also on track, with its preclinical research and unique linker platform selected for a poster presentation at the 2025 American Association for Cancer Research Annual Meeting (AACR 2025)...APL-2401 — a dual FGFR2/3 small molecule inhibitor — has entered IND-enabling studies, with its findings selected for a poster presentation at AACR 2025."

Preclinical • Oncology